DeepMed Research

KERYX BIOPHARMACEUTICALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

Phase 3

Not yet recruiting

Conditions: Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

Interventions: Drug: standard of care
Drug: ferric citrate

First Posted Date: 2020-12-02

Last Posted Date: 2023-10-23

Lead Sponsor: Keryx Biopharmaceuticals

Target Recruit Count: 36

Registration Number: NCT04649411

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

Phase 3

Recruiting

Conditions: Hyperphosphatemia Related to Chronic Kidney Disease

Interventions: Drug: ferric citrate

First Posted Date: 2020-08-24

Last Posted Date: 2025-04-16

Lead Sponsor: Keryx Biopharmaceuticals

Target Recruit Count: 45

Registration Number: NCT04523727

Locations: 🇺🇸
Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States
🇺🇸
University of Alabama at Birmingham (UAB) - Children's of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States

and more 11 locations

KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

Phase 4

Completed

Conditions: Chronic Kidney Diseases
Iron Deficiency Anemia

Interventions: Drug: KRX-0502

First Posted Date: 2017-08-01

Last Posted Date: 2021-03-12

Lead Sponsor: Keryx Biopharmaceuticals

Target Recruit Count: 206

Registration Number: NCT03236246

Locations: 🇺🇸
Miami Kidney Group, Miami, Florida, United States
🇺🇸
Renal Associates, LLC, Columbus, Georgia, United States
🇺🇸
Hypertension and Nephrology Association, Eatontown, New Jersey, United States

and more 21 locations

KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

Phase 3

Completed

Conditions: Anemia of Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: ferric citrate

First Posted Date: 2014-10-20

Last Posted Date: 2018-03-22

Lead Sponsor: Keryx Biopharmaceuticals

Target Recruit Count: 234

Registration Number: NCT02268994

Locations: 🇺🇸
California Renal Research, Glendale, California, United States
🇺🇸
Academic Medical Research Institute, Inc, Los Angeles, California, United States
🇺🇸
Kidney Care Associates, LLC, Augusta, Georgia, United States

and more 33 locations

A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia

Phase 2

Completed

Conditions: Anemia of Chronic Kidney Disease

Interventions: Drug: KRX-0502

First Posted Date: 2014-05-01

Last Posted Date: 2018-08-24

Lead Sponsor: Keryx Biopharmaceuticals

Target Recruit Count: 32

Registration Number: NCT02128074

Locations: 🇮🇱
Western Galilee Hospital, Nahariya, Israel
🇮🇱
Barzilai Medical Center, Ashkelon, Israel
🇮🇱
Nazareth Hospital- EMMS, Nazareth, Israel

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

Phase 2

Completed

Conditions: Iron Deficiency Anemia
Iron Deficiency

Interventions: Drug: Placebo
Drug: Ferric Citrate

First Posted Date: 2012-11-29

Last Posted Date: 2017-10-20

Lead Sponsor: Keryx Biopharmaceuticals

Target Recruit Count: 149

Registration Number: NCT01736397

A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis

Phase 3

Completed

Conditions: End Stage Renal Disease
Kidney Failure
Renal Failure
Hyperphosphatemia
ESRD

Interventions: Drug: ferric citrate

First Posted Date: 2012-03-15

Last Posted Date: 2016-07-13

Lead Sponsor: Keryx Biopharmaceuticals

Target Recruit Count: 168

Registration Number: NCT01554982

Locations: 🇺🇸
Kidney Care Associates, LLC, Augusta, Georgia, United States
🇺🇸
Asheville Kidney Center, Asheville, North Carolina, United States
🇺🇸
University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States

and more 31 locations

A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

Phase 3

Completed

Conditions: Kidney Failure
Hyperphosphatemia

Interventions: Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo

First Posted Date: 2010-08-30

Last Posted Date: 2014-12-10

Lead Sponsor: Keryx Biopharmaceuticals

Target Recruit Count: 441

Registration Number: NCT01191255

Locations: 🇺🇸
Circle Medical Management, Chicago, Illinois, United States
🇺🇸
Cleveland Clinic Foundation Q7-150 Nephrology, Cleveland, Ohio, United States
🇺🇸
Nephrology, PA, Houston, Texas, United States

and more 53 locations

A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

Phase 3

Completed

Conditions: End-Stage Renal Disease
Hyperphosphatemia

Interventions: Drug: ferric citrate

First Posted Date: 2010-02-24

Last Posted Date: 2014-12-04

Lead Sponsor: Keryx Biopharmaceuticals

Target Recruit Count: 154

Registration Number: NCT01074125

Locations: 🇺🇸
Centre Point Dialysis, West Allis, Wisconsin, United States
🇺🇸
Western Nephrology, Westminster, Colorado, United States
🇺🇸
Pines Clinical Research, Inc., Pembroke Pines, Florida, United States

and more 13 locations

Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

Completed

Conditions: End-stage Renal Disease
Hyperphosphatemia
Renal Failure Chronic Requiring Hemodialysis

Interventions: Drug: ferric citrate

First Posted Date: 2009-08-28

Last Posted Date: 2014-12-05

Lead Sponsor: Keryx Biopharmaceuticals

Target Recruit Count: 22

Registration Number: NCT00967993

Locations: 🇮🇱
Barzilai Medical Center Ben-Gurion University, Ashkelon, Israel
🇮🇱
Hadassah University Hospital-Ein Kerem, Jerusalem, Israel
🇮🇱
Assaf Haraofeh Medical Center, Zerifin, Israel

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy